Amdocs (FRA:AOS) 1-Year Sharpe Ratio: -2.61 (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AOS Amdocs Ltd FRA:AOS
73 GF Score
Price €44.44
GF Value €74.61
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Amdocs 1-Year Sharpe Ratio?

Amdocs FRA:AOS +0.07% 73 1-Year Sharpe Ratio is -2.61 as of Jul. 26, 2026. GuruFocus rates FRA:AOS with a GF Score™ of 73/100 and a GF Value™ of €74.61 (Significantly Undervalued). The stock has 2 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-26), Amdocs's 1-Year Sharpe Ratio is -2.61.


Amdocs  (FRA:AOS) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Amdocs 1-Year Sharpe Ratio Related Terms


FRA:AOS vs PATH, S, ACIW: 1-Year Sharpe Ratio Comparison

For the Software - Infrastructure subindustry, Amdocs's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amdocs 1-Year Sharpe Ratio vs Software Industry

For the Software industry and Technology sector, Amdocs's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Amdocs's 1-Year Sharpe Ratio falls into.


FRA:AOS
73GF Score
Amdocs Ltd FRA:AOS
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amdocs 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -2.61 mean?
Amdocs (FRA:AOS) has a 1-Year Sharpe Ratio of -2.61 as of Jul. 26, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Amdocs and its competitors.
Is Amdocs' 1-Year Sharpe Ratio too high?
Amdocs' current 1-Year Sharpe Ratio is -2.61. Overall, Amdocs has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amdocs' 1-Year Sharpe Ratio compare to PATH and S?
Amdocs' 1-Year Sharpe Ratio of -2.61 can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Software company?
A good 1-Year Sharpe Ratio depends on the Software industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Amdocs and its competitors. Amdocs's current 1-Year Sharpe Ratio is -2.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amdocs stock overvalued right now?
Based on GuruFocus' analysis, Amdocs (FRA:AOS) is currently considered Significantly Undervalued. The stock's GF Value™ is €74.61, compared to a current price of €44.44 — trading 40.4% below its estimated fair value. The current 1-Year Sharpe Ratio is -2.61. Amdocs' overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Amdocs (FRA:AOS), the current 1-Year Sharpe Ratio is -2.61 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amdocs (FRA:AOS) Overvalued in 2026?

Based on GuruFocus' analysis, Amdocs stock appears to be undervalued. The current stock price of €44.44 is trading 40.4% below its estimated GF Value™ of €74.61. GuruFocus considers Amdocs to be Significantly Undervalued.

Key valuation signals for FRA:AOS:

  • 1-Year Sharpe Ratio: -2.61
  • GF Value™: €74.61 vs. price of €44.44 (40.4% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the FRA:AOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amdocs Business Description

Address 625 Maryville Centre Drive, Suite 200, Saint Louis, MO, USA, 63141
Amdocs Ltd is a provider of software and services to communications, entertainment, and media service providers. The Company operates in a single segment and designs, develops, markets, supports, implements, and operates open and modular cloud offerings. Its portfolio includes solutions across digital business systems and legacy business and operational support systems, supporting multiple lines of business such as wireless, broadband, cable, fiber, satellite, and digital services. The Company leverages artificial intelligence to support digital transformation, cloud adoption, and intelligent network automation. Geographically, it derives a majority of its revenue from North America and also operates in Europe and the rest of the world.
73GF Score

Get the complete analysis for FRA:AOS

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€44.44
Price
€74.61
GF Value